| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| PAUL STEVEN M | Director | RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON | /s/ Troy Ignelzi, Attorney-in-Fact | 15 Sep 2025 | 0001237564 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RAPP | Common Stock | Purchase | $693K | +28.3K | $24.50 | 28.3K | 12 Sep 2025 | By Paul Capital Strategy III Fund LLC | F1, F2 | |
| transaction | RAPP | Common Stock | Purchase | $334K | +13.4K | +47.31% | $24.97 | 41.7K | 12 Sep 2025 | By Paul Capital Strategy III Fund LLC | F2, F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $23.90 to $24.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. |
| F2 | Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.90 to $25.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. |